XSPRAY
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.
Lue lisääEPS (oik.)
Osinko %
Osavuosikatsaus Q2'26
Osavuosikatsaus Q3'26
Vuosikatsaus '26
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.